Evaluation of colon cancer-specific antigen 2 as a potential serum marker for colorectal cancer

Clinical Cancer Research

Volumn 14, Issue 5, 2008, Pages 1349-1354

  Leman, Eddy S ^a   Schoen, Robert E ^b   Magheli, Ahmed ^a   Sokoll, Lori J ^a   Chan, Daniel W ^a   Getzenberg, Robert H ^a,c  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^c JOHNS HOPKINS HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COLON CANCER SPECIFIC ANTIGEN 2; TUMOR ANTIGEN; TUMOR MARKER; UNCLASSIFIED DRUG;

ADENOMA; ADULT; ADVANCED CANCER; AGED; ANTIGEN DETECTION; ANTIGEN SPECIFICITY; AREA UNDER THE CURVE; ARTICLE; CANCER DIAGNOSIS; COLONOSCOPY; COLORECTAL CANCER; CONFIDENCE INTERVAL; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; POLYP; PRIORITY JOURNAL; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY;

ADENOMA; ADULT; AGED; ANTIGENS, NEOPLASM; COLONOSCOPY; COLORECTAL NEOPLASMS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; MALE; MIDDLE AGED; NUCLEAR PROTEINS; PROGNOSIS; ROC CURVE; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL;

EID: 40949154676     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-07-4110     Document Type: Article

References (13)

1. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer statistics, 2007. CA Cancer J Clin 2007;57:43-66.
2. Bond JH. Clinical evidence for the adenoma-carcinoma sequence, and the management of patients with colorectal adenomas. Semin Gastrointest Dis 2000;11:176-84.
3. Leslie A, Carey FA, Pratt NR, Steele RJ. The colorectal adenoma-carcinoma sequence. Br J Surg 2002;89:845-60.
4. Atkin WS, Morson BC, Cuzick J. Long-term risk of colorectal cancer after excision of rectosigmoid adenomas. N Engl J Med 1992;326:658-62.
5. Mandel JS, Church TR, Ederer F, Bond JH. Colorectal cancer mortality: effectiveness of biennial screening for fecal occult blood. J Natl Cancer Inst 1999;91:434-7.
6. Hawk ET, Levin B. Colorectal cancer prevention. J Clin Oncol 2005;23:378-91.
7. Smith RA, Cokkinides V, von Eschenbach AC, et al. American Cancer Society guidelines for the early detection of cancer. CA Cancer J Clin 2002;52:8-22.
8. Konety BR, Getzenberg RH. Nuclear structural proteins as biomarkers of cancer. J Cell Biochem 1999; Suppl 32-33:183-91.
9. Leman ES, Getzenberg RH. Nuclear structure as a source of cancer specific biomarkers. J Cell Biochem Epub 2007 Apr 23.
10. Brunagel G, Vietmeier BN, Bauer AJ, Schoen RE, Getzenberg RH. Identification of nuclear matrix protein alterations associated with human colon cancer. Cancer Res 2002;62:2437-42.
11. Leman ES, Schoen RE, Weissfeld JL, et al. Initial analyses of colon cancer-specific antigen (CCSA)-3 and CCSA-4 as colorectal cancer-associated serum markers. Cancer Res 2007;67:5600-5.
12. Miller TE, Beausang LA, Winchell LF, Lidgard GP. Detection of nuclear matrix proteins in serum from cancer patients. Cancer Res 1992;52:422-7.
13. Brunagel G, Schoen RE, Getzenberg RH. Colon cancer specific nuclear matrix protein alterations in human colonic adenomatous polyps. J Cell Biochem 2004;91:365-74.